SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser 2003; 919: ix, 1–218, back cover.
  • 2
    Peyron JG. Epidemiological aspects of osteoarthritis. Scand J Rheumatol Suppl 1988; 77: 2933.
  • 3
    Bendele AM. Animal models of osteoarthritis. J Musculoskelet Neuronal Interact 2001; 1: 36376.
  • 4
    Brandt KD. Animal models of osteoarthritis. Biorheology 2002; 39: 22135.
  • 5
    Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM. Gene deletion of either interleukin-1β, interleukin-1β–converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 2003; 48: 345263.
  • 6
    Hayami T, Pickarski M, Wesolowski GA, Mclane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004; 50: 1193206.
  • 7
    Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H, Yamada T, et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage 2005; 13: 63241.
  • 8
    Matsuhashi T, Iwasaki N, Nakagawa H, Hato M, Kurogochi M, Majima T, et al. Alteration of N-glycans related to articular cartilage deterioration after anterior cruciate ligament transection in rabbits. Osteoarthritis Cartilage 2008; 16: 7728.
  • 9
    Heinegard D, Oldberg A. Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J 1989; 3: 204251.
  • 10
    Tavella S, Bellese G, Castagnola P, Martin I, Piccini D, Doliana R, et al. Regulated expression of fibronectin, laminin and related integrin receptors during the early chondrocyte differentiation. J Cell Sci 1997; 110(Pt 18): 226170.
  • 11
    Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985; 232: 71524.
  • 12
    Singh RP, Patarca R, Schwartz J, Singh P, Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 1990; 171: 193142.
  • 13
    Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 147582.
  • 14
    Mori N, Majima T, Iwasaki N, Kon S, Miyakawa K, Kimura C, et al. The role of osteopontin in tendon tissue remodeling after denervation-induced mechanical stress deprivation. Matrix Biol 2007; 26: 4253.
  • 15
    Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279303.
  • 16
    Kon S, Ikesue M, Kimura C, Aoki M, Nakayama Y, Saito Y, et al. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J Exp Med 2008; 205: 2533.
  • 17
    Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998; 13: 110111.
  • 18
    Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101: 146878.
  • 19
    Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001; 193: 399404.
  • 20
    Lee K, Deeds JD, Chiba S, Segre GV. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: a model for intercellular communication in bone. Miner Electrolyte Metab 1995; 21: 1202.
  • 21
    Gerstenfeld LC, Shapiro FD. Expression of bone-specific genes by hypertrophic chondrocytes: implication of the complex functions of the hypertrophic chondrocyte during endochondral bone development. J Cell Biochem 1996; 62: 19.
  • 22
    Pullig O, Weseloh G, Gauer S, Swoboda B. Osteopontin is expressed by adult human osteoarthritic chondrocytes: protein and mRNA analysis of normal and osteoarthritic cartilage. Matrix Biol 2000; 19: 24555.
  • 23
    Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G, Abramson SB, et al. Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum 2001; 44: 57884.
  • 24
    Stoop R, van der Kraan PM, Buma P, Hollander AP, Billinghurst RC, Poole AR, et al. Type II collagen degradation in spontaneous osteoarthritis in C57Bl/6 and BALB/c mice. Arthritis Rheum 1999; 42: 23819.
  • 25
    Chambers MG, Cox L, Chong L, Suri N, Cover P, Bayliss MT, et al. Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum 2001; 44: 145565.
  • 26
    Zemmyo M, Meharra EJ, Kuhn K, Creighton-Achermann L, Lotz M. Accelerated, aging-dependent development of osteoarthritis in α1 integrin–deficient mice. Arthritis Rheum 2003; 48: 287380.
  • 27
    Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971; 53: 52337.
  • 28
    Mankin HJ. Biochemical and metabolic abnormalities in osteoarthritic human cartilage. Fed Proc 1973; 32: 147880.
  • 29
    Bomsta BD, Bridgewater LC, Seegmiller RE. Premature osteoarthritis in the Disproportionate micromelia (Dmm) mouse. Osteoarthritis Cartilage 2006; 14: 47785.
  • 30
    Shimizu S, Asou Y, Itoh S, Chung UI, Kawaguchi H, Shinomiya K, et al. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007; 56: 335865.
  • 31
    Marijnissen AC, Vincken KL, Vos PA, Saris DB, Viergever MA, Bijlsma JW, et al. Knee Images Digital Analysis (KIDA): a novel method to quantify individual radiographic features of knee osteoarthritis in detail. Osteoarthritis Cartilage 2008; 16: 23443.
  • 32
    Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, et al. ADAMTS-1–knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum 2005; 52: 146172.
  • 33
    Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4–knockout mice. Arthritis Rheum 2004; 50: 254758.
  • 34
    Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982; 9: 2478.
  • 35
    Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000; 77: 48798.
  • 36
    Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci U S A 2002; 99: 455661.
  • 37
    Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H, et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003; 112: 1818.
  • 38
    Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004; 21: 53950.
  • 39
    Rosenthal AK, Gohr CM, Uzuki M, Masuda I. Osteopontin promotes pathologic mineralization in articular cartilage. Matrix Biol 2007; 26: 96105.
  • 40
    Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996; 97: 7618.
  • 41
    Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in osteoarthritis. J Clin Invest 1996; 97: 20119.
  • 42
    Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271: 1712431.
  • 43
    Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003; 5: 94103.